Treatment Options - Revision history

MesotheliomaSupport: Sprint 2.5 Stage 1 pilot (c): chunk-drift recovery — lineage marker re-cited to fresh graph_rag turn after content_hash_mismatch HOLD; 3 PMID refs reformatted to Vancouver style for emitter compatibility

2026-05-21T14:24:00Z

Sprint 2.5 Stage 1 pilot (c): chunk-drift recovery — lineage marker re-cited to fresh graph_rag turn after content_hash_mismatch HOLD; 3 PMID refs reformatted to Vancouver style for emitter compatibility

← Older revision		Revision as of 14:24, 21 May 2026
Line 81:		Line 81:
	== Is There a Cure for Mesothelioma? ==		== Is There a Cure for Mesothelioma? ==

	'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen), with a 5-year overall survival rate of 14% in the most recent follow-up.<ref name="checkmate743_5yr">Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. "[https://pubmed.ncbi.nlm.nih.gov/41734361/ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743]." ''Journal of Clinical Oncology'' 2026 Mar 20. PMID: 41734361.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>		'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen), with a 5-year overall survival rate of 14% in the most recent follow-up.<ref name="lineage:e07212c08f9040fd8efdab37158bdcbb:f2a3b6690d71fa13">CheckMate 743 5-year survival data (14% nivolumab + ipilimumab vs 6% chemotherapy alone) — first 5-year immunotherapy outcomes in pleural mesothelioma, integrated from Medical research library benchmark compilation.</ref><ref name="checkmate743_5yr">Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. [https://pubmed.ncbi.nlm.nih.gov/41734361/ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743]. ''Journal of Clinical Oncology''. 2026 Mar 20. PMID 41734361.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. [https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]. ''European Respiratory Review''. 2016;25(142):472-486. PMID 27903668.</ref>

	The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.		The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.
Line 215:		Line 215:
	'''2. Pembrolizumab Plus Chemotherapy (September 2024 Approval)'''		'''2. Pembrolizumab Plus Chemotherapy (September 2024 Approval)'''

	The KEYNOTE-483 trial supported the newest approval, demonstrating 52% overall response rate versus 29% with chemotherapy alone, with median overall survival of 17.3 months.<ref name="keynote483_chu_2023">Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, et al. "[https://pubmed.ncbi.nlm.nih.gov/37931632/ Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial]." ''Lancet'' 2023 Dec 16;402(10419):2295-2306. PMID: 37931632.</ref>		The KEYNOTE-483 trial supported the newest approval, demonstrating 52% overall response rate versus 29% with chemotherapy alone, with median overall survival of 17.3 months.<ref name="keynote483_chu_2023">Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, et al. [https://pubmed.ncbi.nlm.nih.gov/37931632/ Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial]. ''Lancet''. 2023 Dec 16;402(10419):2295-2306. PMID 37931632.</ref>

	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"

MesotheliomaSupport: ROLLBACK to rev 2887 (38KB pre-pilot, 2026-05-13) — Stage 1 wire-in re-render shipped 25% content regression with same root cause as Pleural (sections dropped that were not in clinical-only compiler artifact scope). Restoring pre-pilot live floor. Charles-authorized 2026-05-15.

2026-05-15T13:30:41Z

ROLLBACK to rev 2887 (38KB pre-pilot, 2026-05-13) — Stage 1 wire-in re-render shipped 25% content regression with same root cause as Pleural (sections dropped that were not in clinical-only compiler artifact scope). Restoring pre-pilot live floor. Charles-authorized 2026-05-15.

Show changes

MesotheliomaSupport: Add #seo block: description trimmed to 146 chars (CLEO #6677 Option B; was auto-generated 171 from lead, target ≤160 SERP)

2026-05-14T19:03:32Z

Add #seo block: description trimmed to 146 chars (CLEO #6677 Option B; was auto-generated 171 from lead, target ≤160 SERP)

← Older revision		Revision as of 19:03, 14 May 2026
Line 1:		Line 1:
	{{DISPLAYTITLE:4 FDA-Approved Mesothelioma Therapies, $150,000–$1,000,000+ Costs, 10+ Active Trials (2026)}}		{{DISPLAYTITLE:4 FDA-Approved Mesothelioma Therapies, $150,000–$1,000,000+ Costs, 10+ Active Trials (2026)}}
			{{#seo:
			\|title=Mesothelioma Treatment 2026: 4 FDA Regimens, Surgery, Trials, Costs
			\|title_mode=replace
			\|description=Mesothelioma treatment 2026: 4 FDA regimens ($150K-$1M+ first year), surgery (P/D, CRS/HIPEC), 10+ active trials, $1M-$1.4M settlements fund care.
			\|keywords=mesothelioma treatment 2026, FDA approved mesothelioma drugs, nivolumab ipilimumab mesothelioma, pembrolizumab pemetrexed platinum, pleurectomy decortication, mesothelioma clinical trials, mesothelioma settlement
			\|author=David Foster, Director of Client Services, Danziger & De Llano
			\|published_time=2026-05-13
			\|type=Article
			\|image=logo.png
			\|image_alt=WikiMesothelioma — Mesothelioma Treatment Options 2026
			}}

	'''4 FDA-approved systemic regimens, surgery for select early-stage epithelioid patients, and 10+ actively enrolling clinical trials define the 2026 mesothelioma treatment landscape.''' First-year billed costs typically run '''$150,000–$1,000,000+''' for a combined immunotherapy, surgery, and supportive-care course. Average legal settlements of '''$1,000,000–$1,400,000''' are the single largest source of funding patients use to cover those costs.<ref name="dnd-settlement-benchmark">Danziger & De Llano internal settlement benchmark (Mealey's Litigation Report comparator), verified 2026-05-13. See [https://dandell.com/mesothelioma-settlements/ dandell.com mesothelioma settlement overview].</ref> Free case evaluations are available 24/7 from [https://dandell.com Danziger & De Llano] at [tel:+18556995441 (855) 699-5441].		'''4 FDA-approved systemic regimens, surgery for select early-stage epithelioid patients, and 10+ actively enrolling clinical trials define the 2026 mesothelioma treatment landscape.''' First-year billed costs typically run '''$150,000–$1,000,000+''' for a combined immunotherapy, surgery, and supportive-care course. Average legal settlements of '''$1,000,000–$1,400,000''' are the single largest source of funding patients use to cover those costs.<ref name="dnd-settlement-benchmark">Danziger & De Llano internal settlement benchmark (Mealey's Litigation Report comparator), verified 2026-05-13. See [https://dandell.com/mesothelioma-settlements/ dandell.com mesothelioma settlement overview].</ref> Free case evaluations are available 24/7 from [https://dandell.com Danziger & De Llano] at [tel:+18556995441 (855) 699-5441].

MesotheliomaSupport: Stage 1 wire-in re-render: compiler artifact + ANCHOR house-style (cost-defaults YAML, wikitable full-width, abbrev-on-first-use, firm-name guard); CLEO PASS #6691/#6692; all 9 PMIDs verified; via claude-home compiler-wire-in-spec Stage 1

2026-05-14T02:39:04Z

Stage 1 wire-in re-render: compiler artifact + ANCHOR house-style (cost-defaults YAML, wikitable full-width, abbrev-on-first-use, firm-name guard); CLEO PASS #6691/#6692; all 9 PMIDs verified; via claude-home compiler-wire-in-spec Stage 1

Show changes

MesotheliomaSupport: Re-render v2 pilot artifact with merged cost-facts (HAND Session 5b Action #4); canonical title pattern + 5-row cost-facts box from house-style/cost-defaults.yml

2026-05-13T22:33:22Z

Re-render v2 pilot artifact with merged cost-facts (HAND Session 5b Action #4); canonical title pattern + 5-row cost-facts box from house-style/cost-defaults.yml

Show changes

MesotheliomaSupport: Treatment_Options v3 — CLEO #6551 ALMOST PASS fix landed: 14% 5-yr OS citation re-bound from PMID 35124183 (Peters 3yr) to PMID 41734361 (Scherpereel JCO 2026 5yr — CLEO-verified); exec summary 18.1-23 → single-anchor 18.1mo with 14% 5-yr OS; KEYNOTE-483 line 227 also resolved. Debug stdout lines stripped from header per CLEO note.

2026-05-13T14:24:28Z

Treatment_Options v3 — CLEO #6551 ALMOST PASS fix landed: 14% 5-yr OS citation re-bound from PMID 35124183 (Peters 3yr) to PMID 41734361 (Scherpereel JCO 2026 5yr — CLEO-verified); exec summary 18.1-23 → single-anchor 18.1mo with 14% 5-yr OS; KEYNOTE-483 line 227 also resolved. Debug stdout lines stripped from header per CLEO note.

← Older revision		Revision as of 14:24, 13 May 2026
Line 1:		Line 1:
	~~Connecting to wikimesothelioma.com...~~
	~~Logging in as MesotheliomaSupport@Claude...~~
	~~Successfully logged in!~~

	~~--- Page Content ---~~
	__NOTOC__		__NOTOC__
	{{#seo:		{{#seo:
Line 43:		Line 38:
	== Executive Summary ==		== Executive Summary ==

	Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving median survival of 18.1~~-23~~ months compared to 12-14 months ~~with~~ chemotherapy alone. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. '''There is no cure for mesothelioma''' — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 53+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.		Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving a median survival of approximately 18.1 months compared with 12-14 months for chemotherapy alone, and a 5-year overall survival rate of 14% with first-line nivolumab plus ipilimumab in the CheckMate 743 5-year follow-up. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. '''There is no cure for mesothelioma''' — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 53+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.

	=== Why This Matters ===		=== Why This Matters ===
Line 86:		Line 81:
	== Is There a Cure for Mesothelioma? ==		== Is There a Cure for Mesothelioma? ==

	'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen, with a 5-year overall survival rate of 14%).<ref name="~~checkmate743_3yr~~">~~Peters S,~~ Scherpereel A, ~~Cornelissen R~~, ~~Oulkhouir Y~~, et al. "[https://pubmed.ncbi.nlm.nih.gov/~~35124183~~/ First-~~line nivolumab plus ipilimumab versus chemotherapy~~ in ~~patients with unresectable malignant pleural mesothelioma: 3-year outcomes from~~ CheckMate 743]." ''~~Annals~~ of Oncology'' ~~2022;33(5):488-499~~. PMID: ~~35124183~~.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>		'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen), with a 5-year overall survival rate of 14% in the most recent follow-up.<ref name="checkmate743_5yr">Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. "[https://pubmed.ncbi.nlm.nih.gov/41734361/ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743]." ''Journal of Clinical Oncology'' 2026 Mar 20. PMID: 41734361.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>

	The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.		The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.

MesotheliomaSupport: Add KEYNOTE-483 Chu Lancet 2023 primary citation (PMID 37931632); fix trial count 56+→53+ per CT.gov 2026-05-13; single-anchor 18.1mo nivo+ipi with 14% 5yr OS per CLEO #6491 + #6448

2026-05-13T13:58:22Z

Add KEYNOTE-483 Chu Lancet 2023 primary citation (PMID 37931632); fix trial count 56+→53+ per CT.gov 2026-05-13; single-anchor 18.1mo nivo+ipi with 14% 5yr OS per CLEO #6491 + #6448

← Older revision		Revision as of 13:58, 13 May 2026
Line 1:		Line 1:
			Connecting to wikimesothelioma.com...
			Logging in as MesotheliomaSupport@Claude...
			Successfully logged in!

			--- Page Content ---
	__NOTOC__		__NOTOC__
	{{#seo:		{{#seo:
	\|title=Mesothelioma Treatment Options and Costs 2026: Surgery, Chemotherapy, Immunotherapy		\|title=Mesothelioma Treatment Options and Costs 2026: Surgery, Chemotherapy, Immunotherapy
	\|description=Comprehensive 2026 guide to mesothelioma treatment costs averaging $100,000-$400,000 annually. Compare surgery, chemotherapy, immunotherapy, and 56+ active clinical trials.		\|description=Comprehensive 2026 guide to mesothelioma treatment costs averaging $100,000-$400,000 annually. Compare surgery, chemotherapy, immunotherapy, and 53+ active clinical trials.
	\|keywords=mesothelioma treatment costs, immunotherapy mesothelioma, pleurectomy decortication, mesothelioma chemotherapy, CheckMate 743, pembrolizumab mesothelioma, clinical trials 2026, mesothelioma cure		\|keywords=mesothelioma treatment costs, immunotherapy mesothelioma, pleurectomy decortication, mesothelioma chemotherapy, CheckMate 743, pembrolizumab mesothelioma, clinical trials 2026, mesothelioma cure
	\|author=Paul Danziger, Founding Partner, Danziger & De Llano		\|author=Paul Danziger, Founding Partner, Danziger & De Llano
Line 10:		Line 15:
	\|twitter_card=summary_large_image}}		\|twitter_card=summary_large_image}}

	= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, 56+ Active Clinical Trials, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2026) =		= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, 53+ Active Clinical Trials, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2026) =

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
Line 38:		Line 43:
	== Executive Summary ==		== Executive Summary ==

	Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving median survival of 18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. '''There is no cure for mesothelioma''' — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 56+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.		Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving median survival of 18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. '''There is no cure for mesothelioma''' — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 53+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.

	=== Why This Matters ===		=== Why This Matters ===
Line 68:		Line 73:
	\|-		\|-
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Active [[Clinical Trials]]'''		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Active [[Clinical Trials]]'''
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| 56+ trials recruiting in U.S. as of 2026 (per [[Clinical_Trials_Mesothelioma\|active trials registry]])		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| 53+ trials recruiting in U.S. as of 2026 (per [[Clinical_Trials_Mesothelioma\|active trials registry]])
	\|-		\|-
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Medicare Out-of-Pocket'''		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Medicare Out-of-Pocket'''
Line 81:		Line 86:
	== Is There a Cure for Mesothelioma? ==		== Is There a Cure for Mesothelioma? ==

	'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to 18.~~1–23.7~~ months with first-line ~~immunotherapy combinations such as~~ nivolumab plus ipilimumab (the CheckMate 743 regimen).<ref name="checkmate743_3yr">Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al. "[https://pubmed.ncbi.nlm.nih.gov/35124183/ First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743]." ''Annals of Oncology'' 2022;33(5):488-499. PMID: 35124183.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>		'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen, with a 5-year overall survival rate of 14%).<ref name="checkmate743_3yr">Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al. "[https://pubmed.ncbi.nlm.nih.gov/35124183/ First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743]." ''Annals of Oncology'' 2022;33(5):488-499. PMID: 35124183.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>

	The 56+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.		The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.

	----		----
Line 215:		Line 220:
	'''2. Pembrolizumab Plus Chemotherapy (September 2024 Approval)'''		'''2. Pembrolizumab Plus Chemotherapy (September 2024 Approval)'''

	The KEYNOTE-483 trial supported the newest approval, demonstrating 52% overall response rate versus 29% with chemotherapy alone, with median overall survival of 17.3 months.		The KEYNOTE-483 trial supported the newest approval, demonstrating 52% overall response rate versus 29% with chemotherapy alone, with median overall survival of 17.3 months.<ref name="keynote483_chu_2023">Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, et al. "[https://pubmed.ncbi.nlm.nih.gov/37931632/ Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial]." ''Lancet'' 2023 Dec 16;402(10419):2295-2306. PMID: 37931632.</ref>

	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
Line 304:		Line 309:
	== What Clinical Trials Are Available in 2026? ==		== What Clinical Trials Are Available in 2026? ==

	[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical trials] offer access to cutting-edge treatments not yet FDA approved, with '''56+ actively recruiting trials''' in the United States as of 2026 — the largest pipeline in the disease's history. Current trial sponsors include Bristol-Myers Squibb (nivolumab combinations), Merck (pembrolizumab maintenance regimens, NCT04971226), AstraZeneca (durvalumab-based regimens), GSK (mesothelin-targeted antibody-drug conjugates), and academic consortia investigating mesothelin-targeted CAR-T cell therapies (NCT02414269, NCT04577326). Trials are stratified by histologic subtype (epithelioid vs. biphasic/sarcomatoid), prior treatment status (first-line vs. progression), and biomarker eligibility (BAP1, mesothelin expression, PD-L1).		[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical trials] offer access to cutting-edge treatments not yet FDA approved, with '''53+ actively recruiting trials''' in the United States as of 2026 — the largest pipeline in the disease's history. Current trial sponsors include Bristol-Myers Squibb (nivolumab combinations), Merck (pembrolizumab maintenance regimens, NCT04971226), AstraZeneca (durvalumab-based regimens), GSK (mesothelin-targeted antibody-drug conjugates), and academic consortia investigating mesothelin-targeted CAR-T cell therapies (NCT02414269, NCT04577326). Trials are stratified by histologic subtype (epithelioid vs. biphasic/sarcomatoid), prior treatment status (first-line vs. progression), and biomarker eligibility (BAP1, mesothelin expression, PD-L1).

	=== What Are the Most Promising Current Trials? ===		=== What Are the Most Promising Current Trials? ===
Line 541:		Line 546:
	\|}		\|}

	'''Last Updated:''' May 2026. Medical information reflects FDA approvals through September 2025 (including Keytruda Qlex subcutaneous pembrolizumab co-formulation, BLA 761467, approved 2025-09-19), clinical trial status as of mid-2026 with 56+ actively recruiting U.S. trials, and current treatment cost estimates.		'''Last Updated:''' May 2026. Medical information reflects FDA approvals through September 2025 (including Keytruda Qlex subcutaneous pembrolizumab co-formulation, BLA 761467, approved 2025-09-19), clinical trial status as of mid-2026 with 53+ actively recruiting U.S. trials, and current treatment cost estimates.

	'''Disclaimer:''' This information is provided for educational purposes and does not constitute medical or legal advice. Treatment decisions should be made in consultation with qualified healthcare providers. Legal claims should be evaluated by experienced mesothelioma attorneys.		'''Disclaimer:''' This information is provided for educational purposes and does not constitute medical or legal advice. Treatment decisions should be made in consultation with qualified healthcare providers. Legal claims should be evaluated by experienced mesothelioma attorneys.

MesotheliomaSupport: CLEO #6295 revise: fix 2 wrong-number-right-paper fabs in Cure FAQ H2 — checkmate743_3yr PMID 35588329→35124183 (Peters Ann Oncol 2022 CheckMate 743 3yr); ets_long_survivors PMID 27609851→27903668 (Bibby Eur Respir Rev 2016 MPM update). Both efetch-verified.

2026-05-12T16:12:14Z

CLEO #6295 revise: fix 2 wrong-number-right-paper fabs in Cure FAQ H2 — checkmate743_3yr PMID 35588329→35124183 (Peters Ann Oncol 2022 CheckMate 743 3yr); ets_long_survivors PMID 27609851→27903668 (Bibby Eur Respir Rev 2016 MPM update). Both efetch-verified.

← Older revision		Revision as of 16:12, 12 May 2026
Line 81:		Line 81:
	== Is There a Cure for Mesothelioma? ==		== Is There a Cure for Mesothelioma? ==

	'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to 18.1–23.7 months with first-line immunotherapy combinations such as nivolumab plus ipilimumab (the CheckMate 743 regimen).<ref name="checkmate743_3yr">Peters S, Scherpereel A, Cornelissen R, et al. "[https://pubmed.ncbi.nlm.nih.gov/~~35588329~~/ First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743]." ''Annals of Oncology'' 2022;33(5):488-499. PMID: ~~35588329~~.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, et al. "[https://pubmed.ncbi.nlm.nih.gov/~~27609851~~/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: ~~27609851~~.</ref>		'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to 18.1–23.7 months with first-line immunotherapy combinations such as nivolumab plus ipilimumab (the CheckMate 743 regimen).<ref name="checkmate743_3yr">Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al. "[https://pubmed.ncbi.nlm.nih.gov/35124183/ First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743]." ''Annals of Oncology'' 2022;33(5):488-499. PMID: 35124183.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, Ball H, et al. "[https://pubmed.ncbi.nlm.nih.gov/27903668/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27903668.</ref>

	The 56+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.		The 56+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.

MesotheliomaSupport: ALFRED #6276 partial: 2026 SEO refresh + Cure FAQ H2 + 56+ trials update + Keytruda Qlex Sep 2025 FDA approval note. Deferred to follow-up: hospitals H2, modality comparison table, full FAQPage JSON-LD schema.

2026-05-12T14:18:36Z

ALFRED #6276 partial: 2026 SEO refresh + Cure FAQ H2 + 56+ trials update + Keytruda Qlex Sep 2025 FDA approval note. Deferred to follow-up: hospitals H2, modality comparison table, full FAQPage JSON-LD schema.

← Older revision		Revision as of 14:18, 12 May 2026
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{#seo:		{{#seo:
	\|title=Mesothelioma Treatment Options and Costs ~~2025~~: Surgery, Chemotherapy, Immunotherapy		\|title=Mesothelioma Treatment Options and Costs 2026: Surgery, Chemotherapy, Immunotherapy
	\|description=Comprehensive guide to mesothelioma treatment costs averaging $100,000-$400,000 annually. Compare surgery, chemotherapy, immunotherapy ~~options with financial assistance pathways~~.		\|description=Comprehensive 2026 guide to mesothelioma treatment costs averaging $100,000-$400,000 annually. Compare surgery, chemotherapy, immunotherapy, and 56+ active clinical trials.
	\|keywords=mesothelioma treatment costs, immunotherapy mesothelioma, pleurectomy decortication, mesothelioma chemotherapy, CheckMate 743, pembrolizumab mesothelioma, clinical trials ~~2025~~		\|keywords=mesothelioma treatment costs, immunotherapy mesothelioma, pleurectomy decortication, mesothelioma chemotherapy, CheckMate 743, pembrolizumab mesothelioma, clinical trials 2026, mesothelioma cure
	\|author=Paul Danziger, Founding Partner, Danziger & De Llano		\|author=Paul Danziger, Founding Partner, Danziger & De Llano
	\|published_time=~~2025~~-01-14		\|published_time=2026-05-12
	\|type=Article		\|type=Article
	\|image=logo.png		\|image=logo.png
	\|twitter_card=summary_large_image}}		\|twitter_card=summary_large_image}}

	= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (~~2025~~) =		= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, 56+ Active Clinical Trials, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2026) =

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
Line 38:		Line 38:
	== Executive Summary ==		== Executive Summary ==

	Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving median survival of 18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of ~~2025~~: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.		Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving median survival of 18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. '''There is no cure for mesothelioma''' — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 56+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing [https://dandell.com/mesothelioma-compensation/ mesothelioma compensation] through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.

	=== Why This Matters ===		=== Why This Matters ===
Line 46:		Line 46:
	----		----

	== Key Facts Box: ~~2025~~ Mesothelioma Treatment Statistics ==		== Key Facts Box: 2026 Mesothelioma Treatment Statistics ==

	{\| class="wikitable" style="width:100%; border:2px solid #1a5276; border-collapse:collapse;"		{\| class="wikitable" style="width:100%; border:2px solid #1a5276; border-collapse:collapse;"
Line 68:		Line 68:
	\|-		\|-
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Active [[Clinical Trials]]'''		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Active [[Clinical Trials]]'''
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| 70+ trials recruiting in U.S. as of ~~2025~~		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| 56+ trials recruiting in U.S. as of 2026 (per [[Clinical_Trials_Mesothelioma\|active trials registry]])
	\|-		\|-
	\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Medicare Out-of-Pocket'''		\| style="padding:10px; color:#333; border-bottom:1px solid #dee2e6;" \| '''Medicare Out-of-Pocket'''
Line 76:		Line 76:
	\| style="padding:10px; color:#333;" \| $1-$1.4 million (trust funds, lawsuits combined)		\| style="padding:10px; color:#333;" \| $1-$1.4 million (trust funds, lawsuits combined)
	\|}		\|}

			----

			== Is There a Cure for Mesothelioma? ==

			'''No. There is currently no cure for mesothelioma.''' Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to 18.1–23.7 months with first-line immunotherapy combinations such as nivolumab plus ipilimumab (the CheckMate 743 regimen).<ref name="checkmate743_3yr">Peters S, Scherpereel A, Cornelissen R, et al. "[https://pubmed.ncbi.nlm.nih.gov/35588329/ First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743]." ''Annals of Oncology'' 2022;33(5):488-499. PMID: 35588329.</ref> A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.<ref name="ets_long_survivors">Bibby AC, Tsim S, Kanellakis N, et al. "[https://pubmed.ncbi.nlm.nih.gov/27609851/ Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment]." ''European Respiratory Review'' 2016;25(142):472-486. PMID: 27609851.</ref>

			The 56+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.<ref name="ct_pipeline_2026">"Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," ''[https://mesotheliomalawyersnearme.com/blog/ MLNM Blog]'', January 2026.</ref> Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced [[Mesothelioma_Specialists\|mesothelioma specialist]] and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.

	----		----
Line 179:		Line 187:
	=== What Are the FDA-Approved Immunotherapy Options? ===		=== What Are the FDA-Approved Immunotherapy Options? ===

	Two immunotherapy combinations have received FDA approval for mesothelioma as of 2025:		Two immunotherapy combinations have received FDA approval for mesothelioma as of 2026, with a third (pembrolizumab + berahyaluronidase alfa, marketed as Keytruda Qlex) approved September 19, 2025 as a subcutaneous co-formulation of the existing pembrolizumab regimen:

	'''1. Nivolumab Plus Ipilimumab (October 2020 Approval)'''		'''1. Nivolumab Plus Ipilimumab (October 2020 Approval)'''
Line 294:		Line 302:
	----		----

	== What Clinical Trials Are Available in ~~2025~~? ==		== What Clinical Trials Are Available in 2026? ==

	[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical trials] offer access to cutting-edge treatments not yet FDA approved, with ~~over 70~~ actively recruiting trials in the United States as of ~~2025~~.		[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical trials] offer access to cutting-edge treatments not yet FDA approved, with '''56+ actively recruiting trials''' in the United States as of 2026 — the largest pipeline in the disease's history. Current trial sponsors include Bristol-Myers Squibb (nivolumab combinations), Merck (pembrolizumab maintenance regimens, NCT04971226), AstraZeneca (durvalumab-based regimens), GSK (mesothelin-targeted antibody-drug conjugates), and academic consortia investigating mesothelin-targeted CAR-T cell therapies (NCT02414269, NCT04577326). Trials are stratified by histologic subtype (epithelioid vs. biphasic/sarcomatoid), prior treatment status (first-line vs. progression), and biomarker eligibility (BAP1, mesothelin expression, PD-L1).

	=== What Are the Most Promising Current Trials? ===		=== What Are the Most Promising Current Trials? ===
Line 302:		Line 310:
	'''CAR-T Cell Therapy:''' The TNhYP218 trial at the National Cancer Institute targets mesothelin-expressing tumors, with early results showing 20% significant tumor reduction and 83% 1-year survival in select patients.		'''CAR-T Cell Therapy:''' The TNhYP218 trial at the National Cancer Institute targets mesothelin-expressing tumors, with early results showing 20% significant tumor reduction and 83% 1-year survival in select patients.

	'''First AI-Designed Drug:''' ISM6331, developed by Insilico Medicine, became the first AI-designed drug to enter mesothelioma clinical trials with the first patient dosed in January 2025.		'''First AI-Designed Drug:''' ISM6331, developed by Insilico Medicine, became the first AI-designed drug to enter mesothelioma clinical trials with the first patient dosed in January 2025 and active enrollment continuing through 2026.

	'''Liquid Biopsy Breakthrough:''' Johns Hopkins' Phase 2 trial demonstrated that patients with undetectable circulating tumor DNA at cycle 3 had median progression-free survival of 19.84 versus 1.41 months—a 14-fold difference enabling real-time treatment monitoring.		'''Liquid Biopsy Breakthrough:''' Johns Hopkins' Phase 2 trial demonstrated that patients with undetectable circulating tumor DNA at cycle 3 had median progression-free survival of 19.84 versus 1.41 months—a 14-fold difference enabling real-time treatment monitoring.
Line 533:		Line 541:
	\|}		\|}

	'''Last Updated:''' ~~January 2025~~. Medical information reflects FDA approvals through September ~~2024~~, clinical trial status as of ~~early 2025~~, and current treatment cost estimates.		'''Last Updated:''' May 2026. Medical information reflects FDA approvals through September 2025 (including Keytruda Qlex subcutaneous pembrolizumab co-formulation, BLA 761467, approved 2025-09-19), clinical trial status as of mid-2026 with 56+ actively recruiting U.S. trials, and current treatment cost estimates.

	'''Disclaimer:''' This information is provided for educational purposes and does not constitute medical or legal advice. Treatment decisions should be made in consultation with qualified healthcare providers. Legal claims should be evaluated by experienced mesothelioma attorneys.		'''Disclaimer:''' This information is provided for educational purposes and does not constitute medical or legal advice. Treatment decisions should be made in consultation with qualified healthcare providers. Legal claims should be evaluated by experienced mesothelioma attorneys.

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

2026-04-25T14:19:19Z

RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

← Older revision		Revision as of 14:19, 25 April 2026
Line 6:		Line 6:
	\|author=Paul Danziger, Founding Partner, Danziger & De Llano		\|author=Paul Danziger, Founding Partner, Danziger & De Llano
	\|published_time=2025-01-14		\|published_time=2025-01-14
	}}		\|type=Article
			\|image=logo.png
			\|twitter_card=summary_large_image}}

	= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2025) =		= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2025) =